skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Immunosuppression in irradiated breast cancer patients: In vitro effect of cyclooxygenase inhibitors

Journal Article · · Bulletin of the New York Academy of Medicine; (USA)
OSTI ID:7104939

We have documented in previous studies that local irradiation therapy for breast cancer caused severe lymphopenia with reduction of both T and non-T lymphocytes. Non-T cells were relatively more depressed but recovered within six months. The recovery of T cells, on the other hand, remained incomplete 10-11 years after irradiation. Several lymphocyte functions were also severely impaired. An association was found between prognosis and postirradiation mitogen reactivity of lymphocytes from these patients. Mortality up to eight years after irradiation was significantly higher in patients with low postirradiation phytohemagglutinin and PPD reactivity. The radiation induced decrease in mitogenic response seemed mainly to be caused by immunosuppressive monocytes, which suggests that the underlying mechanism might be mediated by increased production of prostaglandins by monocytes. For this reason we examined the effect of some cyclooxygenase products on different lymphocyte functions and found that prostaglandins A2, D2, and E2 inhibited phytohemagglutinin response in vitro. Natural killer cell activity was also reduced by prostaglandins D2 and E2. The next step was to examine various inhibitors of cyclooxygenase in respect to their capacity to revert irradiation-induced suppression of in vitro mitogen response in lymphocytes from breast cancer patients. It was demonstrated that Diclofenac Na (Voltaren), Meclofenamic acid, Indomethacin, and lysin-mono-acetylsalicylate (Aspisol) could enhance mitogen responses both before and after radiation therapy. This effect was most pronounced at completion of irradiation. On a molar basis, Diclofenac Na was most effective followed by Indomethacin, Meclofenamic acid, and lysin-monoacetylsalicylate.

OSTI ID:
7104939
Journal Information:
Bulletin of the New York Academy of Medicine; (USA), Vol. 65:1; ISSN 0028-7091
Country of Publication:
United States
Language:
English

Similar Records

HIV-mediated immunodepression: in vitro inhibition of T-lymphocyte proliferative response by ultraviolet-inactivated virus
Journal Article · Fri Jan 01 00:00:00 EST 1988 · Clin. Immunol. Immunopathol.; (United States) · OSTI ID:7104939

Lymphoid irradiation in intractable rheumatoid arthritis. Long-term followup of patients treated with 750 rads or 2,000 rads
Journal Article · Mon May 01 00:00:00 EDT 1989 · Arthritis Rheum.; (United States) · OSTI ID:7104939

Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
Journal Article · Fri Apr 15 00:00:00 EDT 2005 · Experimental Cell Research · OSTI ID:7104939